The global point of care infectious disease testing market size is expected to reach USD 15.76 billion by 2030, registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.
Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in point-of-care infectious disease diagnostics market through to 2025.
For instance, development of a new ‘lab-on-a-disc’ technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.
Request a free sample copy or view report summary: Point Of Care Infectious Disease Testing Market Report
COVID-19 segment dominated the market and accounted for a share of 67% in 2023. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions.
Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device.
The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities.
Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support
Grand View Research has segmented the global point of care infectious disease testing market report based on technology, disease, end use, and region:
POC Infectious Disease Testing Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Lateral Flow Immunoassay
Agglutination Test
Flow-through test/Immunoconcentration Assay
Molecular Diagnostics
Others
POC Infectious Disease Testing Disease Outlook (Revenue, USD Billion, 2018 - 2030)
HIV POC
Clostridium Difficile POC
HBV POC
Pneumonia Or Streptococcus Associated Infections
Respiratory Syncytial Virus (RSV) POC
HPV POC
Influenza/Flu POC
HCV POC
MRSA POC
TB & Drug-resistant TB POC
HSV POC
COVID-19
Other Infectious Diseases
POC Infectious Disease Testing End Use Outlook (Revenue, USD Billion, 2018 - 2030)
Clinics
Hospitals
Home
Assisted Living Healthcare Facilities
Laboratory
POC Infectious Disease Testing Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Point Of Care (POC) Infectious Disease Testing Market
Abbott
Thermo Fisher Scientific Inc
F. Hoffmann-La Roche Ltd
Siemens Healthineers
Becton, Dickinson & Company
Chembio Diagnostics Inc.
Trinity Biotech
Cardinal Health
Quest Diagnostics Incorporated
Bio-Rad Laboratories Inc.
bioMérieux SA
Sight Diagnostics Ltd.
Gene POC
Trivitron Healthcare
OJ-Bio Ltd.
Ortho-Clinical Diagnostics.
"The quality of research they have done for us has been excellent..."